Definition

A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from the patient’s resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs BST02 specifically recognize and kill the patient’s tumor cells.